Volker Heinemann, MD, PhD

Videos

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.

The Need for Better Surrogate Parameters for Overall Survival in Colorectal Cancer

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Role of DPR in Colorectal Cancer

Volker Heinemann, MD, PhD, professor, medical oncology, University of Munich in Munich, Germany, discusses the design and results from the FIRE-3 trial at the 2013 ASCO Annual Meeting.

In the randomized phase III FIRE-3 clinical trial, cetuximab (Erbitux) plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) was compared to bevacizumab (Avastin) plus FOLFIRI for first-line treatment of metastatic colorectal cancer and KRAS wild-type tumors.

In the intent-to-treat population, there was no significant difference observed with regard to objective response rate. Heinemann notes that cetuximab showed benefit in assessable patients. Further, the median time to progression-free survival was nearly the same in the two arms (10.0 vs 10.3 months respectively). Overall survival was markedly longer in the cetuximab arm (28.7 months) compared to the bevacizumab arm (25.0 months).

The FIRE-3 trial was a randomized phase III trial

The trial analyzed FOLFIRI + cetuximab versus FOLFIRI + bevacizumab for metastatic colorectal cancer

In the intent-to-treat population, there was no significant difference with regard to objective response rate

Cetuximab showed benefit among all assessable patients

View all coverage from the 2013 ASCO Meeting

Volker Heinemann, MD, PhD | Authors

Articles

The Need for Better Surrogate Parameters for Overall Survival in Colorectal Cancer

Role of DPR in Colorectal Cancer

The Design and Results of the FIRE-3 Trial